Clinical Trial Update: Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of anti-CLL1 CAR T-cell therapy for relapsed/refractory AML; status not reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• anti-CLL1 CAR T-cell therapy

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: UNKNOWN